Category: ‘Clinical Trials and Studies’
Posted on June 7th, 2022
Posted on January 15th, 2022
Keio University in Tokyo said Friday it has started the world’s first clinical test using induced pluripotent stem cells, or iPS cells, to treat patients with spinal cord injuries.
In the study commenced in December, the university will eventually transplant cells derived from iPS cells to four patients who between two to four weeks earlier lost motor and sensory function after sustaining injuries when playing sport or in traffic accidents.
Posted on January 12th, 2022
The company successfully used human implants for replacing the injured spinal cord of a living pig, thereby simulating the anticipated surgical procedure in humans.
Spinal cord injuries are notoriously difficult to operate on, but an Israeli biotech company has entered a new road on the way to a cure using pigs.
Neuroplast Announces Successful Clinical Phase I Trial with Neuro-Cells Stem Cell Treatment for Traumatic Spinal Cord Injury
Posted on November 11th, 2021
Dutch biotech company, Neuroplast, and the Hospital Nacional de Parapléjicos de Toledo in Spain have announced positive clinical Phase I results after analysis of ten patients suffering from traumatic spinal cord injury (TSCI), with data demonstrating that its investigational stem cell treatment, Neuro-Cells, appears to be safe and well tolerated, without product-related adverse events.
The treatment uses the patient’s own stem cells to prevent further loss of function after sustaining TSCI, in an effort to limit loss of mobility and independence of otherwise life-long impairment.
Posted on September 10th, 2021
A joint group of Chinese scientists has recently confirmed the safety and preliminary effective of NeuroRegen Scaffold transplantation for spinal cord injury repair. Results were published in Science China Life Sciences.